Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis

References

• Beltrani V. S., Boguneiwicz M. Atopic dermatitis. Dermatol Online J 2003 Mar; 9((2))1
   Google Scholar
• Spergel J. M., Paller A. S. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112: S118–27
   PubMed Web of Science ®Google Scholar
• Rudikoff D., Lebwohl D. Atopic dermatitis. Lancet 1998; 351: 1715–21
   PubMed Web of Science ®Google Scholar
• Ellis C., Luger T on behalf of the ICCAD II faculty. International Consensus Conference on Atopic Dermatitis II (ICCAD II): Clinical update and current treatment strategies. Br J Dermatol 2003; 148((suppl 63))3–10
   PubMedGoogle Scholar
• Herd R. M., Tidman M. J., Prescott R. J., Hunter J. A. Prevalence of atopic eczema in the community: The Lothian atopic dermatitis study. Br J Dermatol 1996 Jul; 135: 18–9
   Google Scholar
• Hoare C., Li Wan Po A., Williams H. Systemic review of treatments for atopic eczema. Health Technol Assess 2000; 4: 1–191
   PubMedGoogle Scholar
• Hanifin J. M., Ling M. R., Langley R., Breneman D., Rafal E., Tacrolimus Ointment Study Group. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, Efficacy. J Am Acad Dermatol 2001; 44((suppl))S28–38
   Google Scholar
• Soter N. A., Fleischer A. B., Jr., Webster G. F., Monroe E., Lawrence I., Tacrolimus Ointment Study Group. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, Safety. J Am Acad Dermatol 2001; 44((suppl))S39–46
   Google Scholar
• Paller A., Eichenfield L. F., Leung D. Y. M., Stewart D., Appell M., the Tacrolimus Ointment Study Group. A 12‐week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44((suppl))S47–57
   Google Scholar
• Kang S., Lucky A. W., Pariser D., Lawrence I., Hanifin J. M., the Tacrolimus Ointment Study Group. Long‐term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001; 44((suppl))S58–64
   Google Scholar
• Reitamo S., Wollenberg A., Schopf E., Perrot J. L., Marks R., Ruzicka T., et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136: 999–1006
   PubMed Web of Science ®Google Scholar
• Eichenfield L. F., Lucky A. W., Boguniewicz M., Langley R. G. B., Cherill R., Marshall K., et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495–504
   PubMed Web of Science ®Google Scholar
• Wahn U., Bos J. D., Goodfield M., Caputo R., Papp K., Manjra A., , for the Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group, et al. Efficacy and safety of pimecrolimus cream in the long‐term management of atopic dermatitis in children. Pediatrics 2002; 110((1 Pt 1))e2
   PubMed Web of Science ®Google Scholar
• Meurer M., Fölster‐Holst R., Wozel G., Weidinger G., Junger M., Brautigam M., for the CASM‐DE‐01 Study Group. Pimecrolimus cream in the long‐term management of atopic dermatitis in adults: A six‐month study. Dermatology 2002; 205: 271–7
   PubMed Web of Science ®Google Scholar
• Luger T., Van Leent E. J., Graeber M., Hedgecock S., Thurston M., Kandra A., et al. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001; 144: 788–94
   PubMed Web of Science ®Google Scholar
• Hanifin J. M., Paller A. S., Eichenfield L., Clark R. A., Korman N., Weinstein G., et al. Long‐term (up to 4 years) efficacy and safety of tacrolimus ointment in patients with atopic dermatitis. J Am Acad Dermatol 2005; 53: S186–94
   PubMed Web of Science ®Google Scholar
• Koo J. Y. M., Fleischer A. B., Jr., Abramovits W., Pariser D. M., McCall C. O., Horn T., et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: Results in 8000 patients. J Am Acad Dermatol 2005; 53: S195–205
   PubMed Web of Science ®Google Scholar
• Luger J., Lahfa M., Fölster‐Holst R., Gulliver W. P., Allen R., Molloy S., et al. Long‐term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004; 15: 169–78
   PubMedGoogle Scholar
• Paller A. S., Lebwohl M., Fleischer A. B., Antaya R., Langley R. G., Kirsner A. S., , for the US/Canada Tacrolimus Ointment Study Group, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: Results from 3 randomized, comparative studies. J Am Acad Dermatol 2005; 52: 810–22
   PubMed Web of Science ®Google Scholar
• Hanifin J. M., Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980; 92: 44–7
   Google Scholar
• Hanifin J. M., Thurston M., Omoto M., Cherill R., Tofte S. J., Graeber M., et al. The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis. Exp Dermatol 2001; 10: 11–18
   PubMed Web of Science ®Google Scholar
• Barbier N., Paul C., Luger T., Allen R., De Prost Y., Papp K., et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 2004; 150: 96–102
   PubMed Web of Science ®Google Scholar
• Lübbe J., Friedlander S. F., Cribier B., Morren M‐A., Garcia‐Rodriguez A., Gelmetti C., , on behalf of the NOBEL (New Online Based ELidel) Study Group, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol 2006; 7: 121–31
   PubMed Web of Science ®Google Scholar
• Kempers S., Boguniewicz M., Carter E., Jarratt M., Pariser D., Stewart D., et al. A randomized investigator‐blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004; 51: 515–25
   PubMed Web of Science ®Google Scholar
• Bigby M. Tacrolimus and pimecrolimus for atopic dermatitis. Where do they fit in?. Arch Dermatol 2006; 142: 1203–5
   Google Scholar